UA83484C2 - Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция - Google Patents

Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция Download PDF

Info

Publication number: UA83484C2
Authority: UA; Ukraine
Prior art keywords: aai; aza; miyiza; mkr; aaia
Prior art date: 2003-03-05

Application number

UAA200509283A

Other languages

English (en)

Ukrainian (uk)

Inventor

Меттью Л. Шерман

мл. Гиббонс Джеймс Дж.

Марк Бергер

Роберт Т. Магвайр

Роберт Фридман

Original Assignee

Уайт

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-05

Filing date

2004-01-03

Publication date

2008-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83484(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-03 Application filed by Уайт filed Critical Уайт

2008-07-25 Publication of UA83484C2 publication Critical patent/UA83484C2/ru

Links

229940122815 Aromatase inhibitor Drugs 0.000 title abstract 2
239000003886 aromatase inhibitor Substances 0.000 title abstract 2
206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
208000006123 Myiasis Diseases 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 abstract 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
HKVAMNSJSFKALM-CPXURSODSA-N everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-CPXURSODSA-N 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229960000235 temsirolimus Drugs 0.000 abstract 1
235000013929 Psidium pyriferum Nutrition 0.000 description 2
244000236580 Psidium pyriferum Species 0.000 description 2
229940106943 azor Drugs 0.000 description 2
XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
241000223477 Abea Species 0.000 description 1
101100109406 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aga-1 gene Proteins 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UAA200509283A 2003-03-05 2004-01-03 Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция UA83484C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45228903P	2003-03-05	2003-03-05
PCT/US2004/006354 WO2004078133A2 (en)	2003-03-05	2004-03-01	Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (1)

Publication Number	Publication Date
UA83484C2 true UA83484C2 (ru)	2008-07-25

Family

ID=32962706

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200509283A UA83484C2 (ru)	2003-03-05	2004-01-03	Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция

Country Status (20)

Country	Link
US (1)	US20040176339A1 (ru)
EP (1)	EP1603561A2 (ru)
JP (1)	JP2006519862A (ru)
KR (1)	KR20050109965A (ru)
CN (1)	CN1756549A (ru)
AR (1)	AR043403A1 (ru)
AU (1)	AU2004218439A1 (ru)
BR (1)	BRPI0408024A (ru)
CA (1)	CA2516353A1 (ru)
CR (1)	CR7942A (ru)
EC (1)	ECSP056001A (ru)
MX (1)	MXPA05009246A (ru)
NI (1)	NI200500148A (ru)
NO (1)	NO20054133L (ru)
NZ (1)	NZ542738A (ru)
RU (1)	RU2355399C2 (ru)
TW (1)	TW200529829A (ru)
UA (1)	UA83484C2 (ru)
WO (1)	WO2004078133A2 (ru)
ZA (1)	ZA200508029B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
AU2004261163A1 (en) *	2003-07-25	2005-02-10	Wyeth	CCI-779 lyophilized formulations
DE602004011398T2 (de) *	2004-01-08	2009-01-15	Wyeth	Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
WO2006050461A1 (en) *	2004-10-28	2006-05-11	Wyeth	Use of an mtor inhibitor in treatment of uterine leiomyoma
CN113952338A (zh)	2005-02-03	2022-01-21	综合医院公司	治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) *	2005-11-04	2013-05-22	惠氏公司	mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US9006224B2 (en) *	2005-11-21	2015-04-14	Novartis Ag	Neuroendocrine tumor treatment
DE102006008074B4 (de) *	2006-02-22	2013-08-14	RUHR-UNIVERSITäT BOCHUM	Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
TW200901989A (en) *	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3135285B1 (en)	2008-06-17	2018-08-15	Wyeth LLC	Antineoplastic combinations containing hki-272 and vinorelbine
CN105963313A (zh)	2008-08-04	2016-09-28	惠氏有限责任公司	4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
CA2743242A1 (en) *	2008-11-11	2010-05-20	Eli Lilly And Company	P70 s6 kinase inhibitor and mtor inhibitor combination therapy
KR20190128004A (ko)	2009-04-06	2019-11-13	와이어쓰 엘엘씨	네라티닙을 이용한 유방암의 치료법
WO2010118419A2 (en)	2009-04-10	2010-10-14	Haiyan Qi	Novel anti-aging agents and methods to identify them
EP2648721B1 (de)	2011-01-31	2018-09-19	LUCOLAS-M.D. Ltd.	Kombinationen von aromatase inhibitoren und antioxidanzien
US9682066B2 (en) *	2012-12-04	2017-06-20	University Of Cincinnati	Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) *	2013-07-31	2015-02-05	北京盛诺基医药科技有限公司	一种乳腺癌的治疗方法
EP3738592B1 (en) *	2013-10-08	2022-01-26	AI Therapeutics, Inc.	Rapamycin for the treatment of lymphangioleiomyomatosis
BR112016022598A8 (pt)	2014-04-04	2021-06-29	Ai Therapeutics Inc	composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
CA2963085C (en)	2014-10-07	2023-02-21	Lam Therapeutics, Inc.	An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5A (en) *		1836-08-10	Thomas Blanchard	Machine for mortising solid wooden shells of ships' tackle-blocks
US6A (en) *		1836-08-10	Thomas Blanchard	Machine for forming end pieces of plank blocks for ships
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5066493A (en) *	1978-11-03	1991-11-19	American Home Products Corporation	Rapamycin in treatment of tumors
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
IL102414A (en) *	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
US6002008A (en) *	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6277983B1 (en) *	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
AU2001283139A1 (en) *	2000-08-11	2002-02-25	Wyeth	Method of treating estrogen receptor positive carcinoma
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2269604T (lt) *	2001-02-19	2016-11-10	Novartis Ag	Inkstų solidinių navikų gydymas rapamicino dariniu
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
ATE406892T1 (de) *	2001-04-06	2008-09-15	Wyeth Corp	Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
BR0210101A (pt) *	2001-06-01	2004-06-08	Wyeth Corp	Combinações antineoplásticas
US20030008923A1 (en) *	2001-06-01	2003-01-09	Wyeth	Antineoplastic combinations
UA77200C2 (en) *	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2004
- 2004-01-03 UA UAA200509283A patent/UA83484C2/ru unknown
- 2004-02-26 AR ARP040100603A patent/AR043403A1/es unknown
- 2004-03-01 KR KR1020057016528A patent/KR20050109965A/ko not_active Ceased
- 2004-03-01 US US10/790,488 patent/US20040176339A1/en not_active Abandoned
- 2004-03-01 EP EP04716169A patent/EP1603561A2/en not_active Withdrawn
- 2004-03-01 WO PCT/US2004/006354 patent/WO2004078133A2/en not_active Ceased
- 2004-03-01 CN CNA200480005869XA patent/CN1756549A/zh active Pending
- 2004-03-01 AU AU2004218439A patent/AU2004218439A1/en not_active Withdrawn
- 2004-03-01 MX MXPA05009246A patent/MXPA05009246A/es not_active Application Discontinuation
- 2004-03-01 CA CA002516353A patent/CA2516353A1/en not_active Abandoned
- 2004-03-01 RU RU2005130767/14A patent/RU2355399C2/ru not_active IP Right Cessation
- 2004-03-01 NZ NZ542738A patent/NZ542738A/xx unknown
- 2004-03-01 JP JP2006509002A patent/JP2006519862A/ja active Pending
- 2004-03-01 BR BRPI0408024-6A patent/BRPI0408024A/pt not_active IP Right Cessation
- 2004-03-02 TW TW093105371A patent/TW200529829A/zh unknown
2005
- 2005-08-12 CR CR7942A patent/CR7942A/es not_active Application Discontinuation
- 2005-09-01 NI NI200500148A patent/NI200500148A/es unknown
- 2005-09-05 EC EC2005006001A patent/ECSP056001A/es unknown
- 2005-09-06 NO NO20054133A patent/NO20054133L/no not_active Application Discontinuation
- 2005-10-04 ZA ZA200508029A patent/ZA200508029B/en unknown

Also Published As

Publication number	Publication date
KR20050109965A (ko)	2005-11-22
US20040176339A1 (en)	2004-09-09
NZ542738A (en)	2009-02-28
AR043403A1 (es)	2005-07-27
WO2004078133A3 (en)	2004-11-11
ZA200508029B (en)	2007-04-25
TW200529829A (en)	2005-09-16
EP1603561A2 (en)	2005-12-14
AU2004218439A1 (en)	2004-09-16
ECSP056001A (es)	2006-01-27
BRPI0408024A (pt)	2006-02-14
MXPA05009246A (es)	2005-10-19
NO20054133L (no)	2005-10-03
JP2006519862A (ja)	2006-08-31
CN1756549A (zh)	2006-04-05
NO20054133D0 (no)	2005-09-06
CR7942A (es)	2006-02-07
NI200500148A (es)	2006-03-30
CA2516353A1 (en)	2004-09-16
WO2004078133A2 (en)	2004-09-16
RU2005130767A (ru)	2006-02-10
WO2004078133A8 (en)	2005-09-01
RU2355399C2 (ru)	2009-05-20

Publication	Publication Date	Title
UA83484C2 (ru)	2008-07-25	Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
ES2404563T3 (es)	2013-05-28	Ampliación estereofónica
US3894195A (en)	1975-07-08	Method of and apparatus for aiding hearing and the like
GB2369799B (en)	2004-07-07	Layered polyurethane materials
SE0401967D0 (sv)	2004-08-02	Earphone structure with a composite sound field
AU2002343734A1 (en)	2003-06-10	Edible film
AU2001282698A1 (en)	2002-02-25	Semi-permeable membrane, method for providing electric power and a device
CU20210003A7 (es)	2021-08-06	Una preparación farmacéutica liposomal de mitoxantrona útil en el tratamiento de linfoma no de hodgkin
AU766876B2 (en)	2003-10-23	A method for controlling the directionality of the sound receiving characteristic of a hearing aid and a hearing aid for carrying out the method
MX143125A (es)	1981-03-19	Una banda de transmision de fuerza mejorada
IS6262A (is)	2002-02-08	Peptíð, sem hindra smithæfni veira, og aðferðir við notkun þeirra
AU2003202775A8 (en)	2003-09-16	Headphone
AU2002353062A8 (en)	2003-06-23	Protected underwire
GB1516845A (en)	1978-07-05	Vapour release pack
CA232604S (en)	2025-03-06	Speaker storage bag
ES2192275T3 (es)	2003-10-01	Materiales en banda transpirables que tienen textura a manera de tejido.
Vaculovschi et al.	2022	Employment in the Republic of Moldova in the context of the implementation of the national employment strategy 2017-2021
GB202312329D0 (en)	2023-09-27	Elephant ear bag / I'm back
GB1517938A (en)	1978-07-19	Headphone system
JP3101603U (ja)	2004-06-17	消炎鎮痛補助用貼付材
GB202413824D0 (en)	2024-11-06	Pcm material and system
JP3170251U (ja)	2011-09-08	磁気治療シート
TWI913579B (zh)	2026-02-01	多孔吸煙材料包裝物及包含其之吸煙製品
GB2622121B (en)	2025-09-24	Phosphorescent biodegradable carrier and applicator
MX9203671A (es)	1993-12-01	Procedimiento para la fabricacion de un medio ceramico poroso mediante la utilizacion de un lecho empacado perdido.